Man Group plc Buys 92,701 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Man Group plc grew its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 87.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 199,304 shares of the medical equipment provider's stock after purchasing an additional 92,701 shares during the quarter. Man Group plc owned about 0.29% of Lantheus worth $17,830,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Lantheus by 4.1% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 39,212 shares of the medical equipment provider's stock valued at $3,508,000 after purchasing an additional 1,531 shares during the period. LRI Investments LLC lifted its holdings in shares of Lantheus by 8.4% during the fourth quarter. LRI Investments LLC now owns 3,107 shares of the medical equipment provider's stock worth $278,000 after buying an additional 240 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new stake in shares of Lantheus in the fourth quarter valued at about $2,406,000. Janus Henderson Group PLC grew its stake in shares of Lantheus by 72.7% in the fourth quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider's stock valued at $554,583,000 after acquiring an additional 2,610,118 shares in the last quarter. Finally, Gotham Asset Management LLC increased its position in Lantheus by 4.8% during the fourth quarter. Gotham Asset Management LLC now owns 12,905 shares of the medical equipment provider's stock worth $1,154,000 after acquiring an additional 596 shares during the period. Institutional investors and hedge funds own 99.06% of the company's stock.

Analysts Set New Price Targets

A number of research firms have issued reports on LNTH. B. Riley cut their price objective on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a report on Friday, March 21st. Truist Financial cut their price target on Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. Finally, Wall Street Zen raised Lantheus from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $132.67.

Insider Activity

In other Lantheus news, CFO Robert J. Jr. Marshall sold 10,000 shares of the business's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the transaction, the chief financial officer now owns 113,860 shares of the company's stock, valued at approximately $11,445,207.20. The trade was a 8.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Mary Anne Heino sold 53,107 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the sale, the director now owns 440,399 shares in the company, valued at approximately $41,551,645.65. The trade was a 10.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 63,109 shares of company stock worth $6,016,046. Insiders own 1.50% of the company's stock.

Lantheus Trading Down 1.9%

Lantheus stock traded down $1.41 during trading hours on Thursday, reaching $73.72. 304,947 shares of the stock were exchanged, compared to its average volume of 982,869. The stock has a 50 day moving average of $95.68 and a two-hundred day moving average of $92.64. Lantheus Holdings, Inc. has a twelve month low of $73.18 and a twelve month high of $126.89. The company has a market cap of $5.10 billion, a P/E ratio of 12.27 and a beta of 0.23.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The firm had revenue of $372.76 million during the quarter, compared to the consensus estimate of $377.37 million. During the same period last year, the business earned $1.69 earnings per share. The business's revenue was up .8% compared to the same quarter last year. On average, analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.